OncoPatch, Inc., a medical device company developing targeted surface radiation therapy solutions, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Oncopatch Surface Brachytherapy System, indicated for the surface treatment of localized tumors. The system is designed to deliver targeted radiation therapy to superficial lesions and may be used as a primary treatment or for residual disease following excision of primary or recurrent skin tumors. Oncopatch introduces a distinct, patch-based approach to delivering beta radiation directly to skin cancers and other superficial lesions, enabling precise surface treatment while minimizing exposure to underlying healthy tissue....